Shalby Ltd (SHALBY) is currently trading at 123.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Shalby Limited operates a multi-specialty hospital network anchored by orthopedic and joint-replacement care, complemented by an orthopedic implant manufacturing and distribution business. The company reports 13 hospitals, more than 2,200 beds, 60 domestic OPD clinics, international outreach, and over 200,000 joint replacements performed since inception. The core hospital business delivered strong operating momentum in Q2 FY27 despite slightly lower quarter-on-quarter revenue: surgeries increased 14.3%, occupancy improved to 52%, occupied beds rose 6.2%, and ARPOB increased 4.4%. This indicates volume, utilization, and pricing progress, although operational beds declined 3.5% year-on-year. Consolidated H1 FY27 revenue grew 10.7% and PAT increased 22.9%, but EBITDA margin contracted from 15.9% to 14.5% and PBT declined 13.3%. The contrast highlights improving bottom-line conversion partly alongside margin pressure and continuing weakness in newer or loss-making businesses. Shalby International showed a meaningful turnaround, with H1 revenue rising to ₹559 million and EBITDA moving from a ₹51 million loss to a ₹33 million profit. However, it remained loss-making at the PBT level, while MedTech revenue declined sequentially and its consolidated EBITDA remained modest. The company’s distinctive growth model combines established hospitals, specialty diversification, physician-led brand equity, and proprietary implants. Management is prioritizing occupancy, Mumbai expansion, surgeon engagement, technology adoption, homecare, and prudent capital allocation, while targeting improved ROCE through operational leverage rather than indiscriminate capacity addition.

Over the past 52 weeks, Shalby Ltd has traded between a low of ₹111.00 and a high of ₹243.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Shalby Ltd has a market capitalization of approximately 1,327.44. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Shalby Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 34.82 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,327.44 Cr, Shalby Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Shalby Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Shalby Ltd is 34.82. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Shalby MedTech's Q2 FY27 consolidated revenue was Rs 31.596 crore, 33% below Rs 47.167 crore in Q1 FY27. EBITDA rose to Rs 36.4 lakh from Rs 16.5 lakh, a 121% quarter-on-quarter increase. The company therefore reported lower revenue but higher EBITDA than in the prior quarter.

Shalby reported 715 occupied beds in Q2 FY27, up from 673 in Q2 FY26, while operational beds declined to 1,365 from 1,415. Its average length of stay excluding day-care cases fell to 3.58 days from 3.74 days, alongside surgeries rising to 8,618.

Shalby’s EBITDA margin declined to 18.2% from 19.5% because multiple expenses represented a larger portion of revenue. Materials and consumables reached 25.5%, doctor and consultant fees were 27.2%, and other expenses were 8.4% of revenue.

Shalby reported consolidated Q2 FY27 revenue of Rs 318.2 crore. This was 9.8% higher than Rs 289.9 crore in Q2 FY26, but 6.0% below Rs 338.6 crore in Q1 FY27.